Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 6/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673005 | 0.86 | YTHDC1 (0.41) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL2113717 | 0.85 | YTHDC1 (0.38) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL30471093 | 0.85 | YTHDC1 (0.38) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL30471263 | 0.84 | HDAC1 (0.40) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL19003136 | 0.84 | YTHDC1 (0.39) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL9936995 | 0.84 | HDAC1 (0.40) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL1114173 | 0.82 | PIK3CD (0.40) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL9937266 | 0.82 | HDAC1 (0.37) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL31372903 | 0.82 | PIK3CD (0.40) | YTHDC1ATRHRH3FLT3HDAC1 | |
| SCHEMBL10008246 | 0.82 | YTHDC1 (0.38) | YTHDC1ATRHRH3FLT3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | YTHDC1 4766/4885ATR 507/4885HRH3 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.